1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Serobian, A. Thomas, D.S. Ball, G.E. Denny, W.A. Wakelin, L.P.G. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C10 H14 N5 O6 P 331.222 y 2'-DEOXYADENOSINE-5'-MONOPHOSPHATE DNA linking C9 H14 N3 O7 P 307.197 y 2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE DNA linking C10 H14 N5 O7 P 347.221 y 2'-DEOXYGUANOSINE-5'-MONOPHOSPHATE DNA linking C10 H15 N2 O8 P 322.208 y THYMIDINE-5'-MONOPHOSPHATE DNA linking C34 H38 N8 O2 4 590.718 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM non-polymer US Biopolymers BIPMAA 0161 0006-3525 101 1099 10.1002/BIP.22513 24898663 The Solution Structure of Bis(Phenazine-1-Carboxamide)-DNA Complexes: Mln 944 Binding Corrected and Extended. 2014 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 THE DNA CONFORMATION IS IN THE FORM OF B-DNA. 2426.617 DNA 2 syn polymer 590.718 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM 1 syn non-polymer no no (DT)(DA)(DC)(DG)(DC)(DG)(DT)(DA) TACGCGTA A,B polydeoxyribonucleotide n n n n n n n n -9.732 1 20 A 1 B 16 5.775 A_DT1:DA16_B 1 -48.153 -0.085 -0.971 -0.222 3.074 1 20 A 2 B 15 -2.941 A_DA2:DT15_B 2 5.876 0.046 0.491 0.005 12.152 1 19 A 3 B 14 -1.525 A_DC3:DG14_B 3 -5.069 0.126 0.138 -0.076 1.777 1 19 A 4 B 13 -1.404 A_DG4:DC13_B 4 3.067 -0.478 0.007 -0.136 2.871 1 19 A 5 B 12 -1.985 A_DC5:DG12_B 5 -10.182 0.178 0.416 -0.117 -6.623 1 19 A 6 B 11 1.491 A_DG6:DC11_B 6 -16.757 0.388 0.123 -0.025 -9.421 1 20 A 7 B 10 -1.951 A_DT7:DA10_B 7 -18.946 -0.322 0.186 0.036 0.639 1 20 A 8 B 9 -0.014 A_DA8:DT9_B 8 -19.423 0.017 -0.004 -0.050 3.620 43.426 A A 1 2 10.014 B B 16 15 3.734 7.064 -0.607 0.726 AA_DT1DA2:DT15DA16_BB 1 -21.859 30.986 37.105 0.142 -1.774 3.156 28.068 A A 2 3 2.104 B B 15 14 3.200 1.019 -0.192 -0.361 AA_DA2DC3:DG14DT15_BB 2 2.483 -5.127 27.942 -0.979 0.965 6.944 11.745 A A 3 4 -3.717 B B 14 13 6.928 -0.756 0.667 -0.329 AA_DC3DG4:DC13DG14_BB 3 2.070 -10.175 11.537 0.588 2.747 3.623 34.883 A A 4 5 6.595 B B 13 12 3.414 3.942 -0.801 1.652 AA_DG4DC5:DG12DC13_BB 4 -2.582 4.319 34.573 2.110 0.914 6.717 26.546 A A 5 6 12.554 B B 12 11 6.899 5.659 0.165 0.736 AA_DC5DG6:DC11DG12_BB 5 6.756 -14.988 25.065 -1.594 3.457 3.252 29.961 A A 6 7 -1.351 B B 11 10 3.246 -0.699 -0.410 -0.528 AA_DG6DT7:DA10DC11_BB 6 0.394 -0.762 29.950 -0.879 0.875 3.631 37.351 A A 7 8 -1.096 B B 10 9 3.117 -0.688 2.100 0.690 AA_DT7DA8:DT9DA10_BB 7 13.044 -20.778 35.069 1.174 -1.443 repository Initial release Structure summary Database references 1 0 2013-08-21 1 1 2013-09-04 1 2 2014-09-03 SOLUTION STRUCTURE OF MLN 944-DNA COMPLEXES SOLUTION STRUCTURE OF THE MLN 944-D(TATGCATA)2 COMPLEX PDBE Y PDBE 2013-07-30 REL XR2 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM 32630 SYNTHETIC CONSTRUCT sample AVERAGE ENERGY MINIMISED SOLUTION STRUCTURE FROM 10 NS OF MOLECULAR DYNAMICS DISTANCE RESTRAINTS 1 1 NOESY COSY TOCSY 31P HSQC 15N HSQC 80 mM 5.0 pH 1.0 atm 288.0 K AMBER - MOLECULAR DYNAMICS 10% WATER/90% D2O D.A.CASE,ET.AL. refinement AMBER structure solution TOPSPIN 3.1 700 Bruker Avance XR2 17 2 XR2 XR2 17 A DT 1 n 1 DT 1 A DA 2 n 2 DA 2 A DC 3 n 3 DC 3 A DG 4 n 4 DG 4 A DC 5 n 5 DC 5 A DG 6 n 6 DG 6 A DT 7 n 7 DT 7 A DA 8 n 8 DA 8 A DT 9 n 1 DT 9 B DA 10 n 2 DA 10 B DC 11 n 3 DC 11 B DG 12 n 4 DG 12 B DC 13 n 5 DC 13 B DG 14 n 6 DG 14 B DT 15 n 7 DT 15 B DA 16 n 8 DA 16 B author_and_software_defined_assembly PQS 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A DG 6 0.074 SIDE CHAIN 1 B DG 12 0.057 SIDE CHAIN 1 3.13 0.30 108.30 111.43 A A A O4' C1' N1 DT DT DT 1 1 1 N 1 -3.14 0.50 117.00 113.86 A A A C4 C5 C6 DA DA DA 2 2 2 N 1 3.64 0.50 117.70 121.34 A A A C5 C6 N1 DA DA DA 2 2 2 N 1 -3.98 0.60 118.60 114.62 A A A N1 C6 N6 DA DA DA 2 2 2 N 1 -4.61 0.70 121.90 117.29 A A A N3 C2 O2 DC DC DC 3 3 3 N 1 -5.16 0.80 105.90 100.74 A A A O4' C1' C2' DG DG DG 4 4 4 N 1 2.80 0.30 108.30 111.10 A A A O4' C1' N9 DG DG DG 4 4 4 N 1 -4.51 0.70 121.90 117.39 A A A N3 C2 O2 DC DC DC 5 5 5 N 1 -4.35 0.60 119.90 115.55 A A A N1 C6 O6 DG DG DG 6 6 6 N 1 3.54 0.30 108.30 111.84 A A A O4' C1' N9 DA DA DA 8 8 8 N 1 -3.13 0.50 117.00 113.87 A A A C4 C5 C6 DA DA DA 8 8 8 N 1 3.15 0.50 117.70 120.85 A A A C5 C6 N1 DA DA DA 8 8 8 N 1 -4.53 0.60 118.60 114.07 A A A N1 C6 N6 DA DA DA 8 8 8 N 1 3.55 0.30 108.30 111.85 B B B O4' C1' N1 DT DT DT 9 9 9 N 1 -3.70 0.60 122.30 118.60 B B B N3 C2 O2 DT DT DT 9 9 9 N 1 -3.79 0.50 117.00 113.21 B B B C4 C5 C6 DA DA DA 10 10 10 N 1 3.87 0.50 117.70 121.57 B B B C5 C6 N1 DA DA DA 10 10 10 N 1 -5.58 0.60 118.60 113.02 B B B N1 C6 N6 DA DA DA 10 10 10 N 1 -5.05 0.70 121.90 116.85 B B B N3 C2 O2 DC DC DC 11 11 11 N 1 -4.67 0.70 121.90 117.23 B B B N3 C2 O2 DC DC DC 13 13 13 N 1 2.98 0.30 108.30 111.28 B B B O4' C1' N1 DT DT DT 15 15 15 N 1 -3.63 0.60 122.90 119.27 B B B C6 C5 C7 DT DT DT 15 15 15 N 1 2.84 0.30 108.30 111.14 B B B O4' C1' N9 DA DA DA 16 16 16 N 1 -3.11 0.50 117.00 113.89 B B B C4 C5 C6 DA DA DA 16 16 16 N 1 3.24 0.50 117.70 120.94 B B B C5 C6 N1 DA DA DA 16 16 16 N 1 -4.99 0.60 118.60 113.61 B B B N1 C6 N6 DA DA DA 16 16 16 N 5'-D(*TP*AP*CP*GP*CP*GP*TP*A)-3', 1-METHYL-9-[12-(9-METHYLPHENAZIN-10-IUM-1-YL)-12-OXO-2,11-DIAZA-5,8-DIAZONIADODEC-1-ANOYL]PHENAZIN-10-IUM The Solution Structure of the MLN 944-d(TACGCGTA)2 complex 1 N N 1 N N 2 N N hydrog WATSON-CRICK A DT 1 A N3 DT 1 1_555 B DA 16 B N1 DA 8 1_555 hydrog WATSON-CRICK A DT 1 A O4 DT 1 1_555 B DA 16 B N6 DA 8 1_555 hydrog WATSON-CRICK A DA 2 A N1 DA 2 1_555 B DT 15 B N3 DT 7 1_555 hydrog WATSON-CRICK A DA 2 A N6 DA 2 1_555 B DT 15 B O4 DT 7 1_555 hydrog WATSON-CRICK A DC 3 A N3 DC 3 1_555 B DG 14 B N1 DG 6 1_555 hydrog WATSON-CRICK A DC 3 A N4 DC 3 1_555 B DG 14 B O6 DG 6 1_555 hydrog WATSON-CRICK A DC 3 A O2 DC 3 1_555 B DG 14 B N2 DG 6 1_555 hydrog WATSON-CRICK A DG 4 A N1 DG 4 1_555 B DC 13 B N3 DC 5 1_555 hydrog WATSON-CRICK A DG 4 A N2 DG 4 1_555 B DC 13 B O2 DC 5 1_555 hydrog WATSON-CRICK A DG 4 A O6 DG 4 1_555 B DC 13 B N4 DC 5 1_555 hydrog WATSON-CRICK A DC 5 A N3 DC 5 1_555 B DG 12 B N1 DG 4 1_555 hydrog WATSON-CRICK A DC 5 A N4 DC 5 1_555 B DG 12 B O6 DG 4 1_555 hydrog WATSON-CRICK A DC 5 A O2 DC 5 1_555 B DG 12 B N2 DG 4 1_555 hydrog WATSON-CRICK A DG 6 A N1 DG 6 1_555 B DC 11 B N3 DC 3 1_555 hydrog WATSON-CRICK A DG 6 A N2 DG 6 1_555 B DC 11 B O2 DC 3 1_555 hydrog WATSON-CRICK A DG 6 A O6 DG 6 1_555 B DC 11 B N4 DC 3 1_555 hydrog WATSON-CRICK A DT 7 A N3 DT 7 1_555 B DA 10 B N1 DA 2 1_555 hydrog WATSON-CRICK A DT 7 A O4 DT 7 1_555 B DA 10 B N6 DA 2 1_555 hydrog WATSON-CRICK A DA 8 A N1 DA 8 1_555 B DT 9 B N3 DT 1 1_555 hydrog WATSON-CRICK A DA 8 A N6 DA 8 1_555 B DT 9 B O4 DT 1 1_555 DNA DNA, BIS(PHENAZINE-1-CARBOXAMIDES), MLN 944, INTERCALATION, DRUG DESIGN, ANTICANCER DRUG. 4BZV PDB 1 4BZV 1 8 4BZV 1 8 4BZV A 1 1 8 9 16 4BZV 9 16 4BZV B 1 1 8 BINDING SITE FOR RESIDUE XR2 A 17 Software 8 A DC 3 A DC 3 8 1_555 A DG 4 A DG 4 8 1_555 A DC 5 A DC 5 8 1_555 A DG 6 A DG 6 8 1_555 B DC 11 B DC 3 8 1_555 B DG 12 B DG 4 8 1_555 B DC 13 B DC 5 8 1_555 B DG 14 B DG 6 8 1_555 1 P 1